Inherited immunodeficiency:genetics and therapy Dr Siobhan Burns http://www.ucl.ac.uk/immunity-transplantation. By: UCL Institute of Immunity and Transplantation … Continue reading →

Human Development: Genetics 1 ETSU Online Programs - http://www.etsu.edu/online Module 2- Human Development: Genetics MOD 02 EP 01. By: East Tennessee State University … Continue reading →

Oxford Genetics Introduction Film Introduction to Oxford Genetics DNA Products and Services. By: Ryan Cawood … Continue reading →

Changing Your Genetics! Online And In Person Training with Bios3: bios3training@gmail.com 5% nutrition (Rich Piana) http://5percentnutrition.com/ GASP and BETTER BODIES CLOTHING https://elite1fitgear.refersion.com/c/1... By: bios3training … Continue reading →

By RTT News, September 10, 2014, 12:14:00 PM EDT (RTTNews.com) - Seattle Genetics Inc ( SGEN ) and Genmab A/S (GNMSF.PK) on Wednesday entered into an additional antibody-drug conjugate collaboration. Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive rights to utilize Seattle Genetics' auristatin-based Antibody-Drug Conjugate (ADC) technology with Genmab's HuMax-AXL, an antibody targeting AXL which is expressed on multiple types of solid cancers. Seattle Genetics is also entitled to receive more than $200 million in potential milestone payments and mid-to-high single digit royalties on worldwide net sales of any resulting products. In addition, prior to Genmab's initiation of a Phase III study for any resulting products, Seattle Genetics has the right to exercise an option to increase the royalties to double digits in exchange for a reduction of the milestone payments owed by Genmab. Irrespective of any exercise of option, Genmab remains in full control of development and commercialization. Seattle Genetics and Genmab entered into an ADC collaboration for HuMax-TF-ADC in September 2010. HuMax-TF-ADC, targeting the Tissue Factor antigen, is in a Phase I trial for solid tumors. Seattle Genetics has the right to exercise a co-development option to share all future … Continue reading →

Seattle Genetics, Inc. today announced that the companies have entered into an additional antibody-drug conjugate collaboration. Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive rights to utilize Seattle Genetics auristatin-based ADC technology with Genmabs HuMax-AXL, an antibody targeting AXL which is expressed on multiple types of solid cancers. Seattle Genetics is also entitled to receive more than $200 million in potential milestone payments and mid-to-high single digit royalties on worldwide net sales of any resulting products. In addition, prior to Genmabs initiation of a Phase III study for any resulting products, Seattle Genetics has the right to exercise an option to increase the royalties to double digits in exchange for a reduction of the milestone payments owed by Genmab. Irrespective of any exercise of option, Genmab remains in full control of development and commercialization. This collaboration with Genmab further extends the reach of our industry-leading ADC technology for use with novel oncology targets, while providing us with a compelling financial value proposition as the program advances, said Natasha Hernday, Vice President, Corporate Development at Seattle Genetics. Genmabs impressive track record in the development of antibody-based therapies for the treatment of cancer, including an … Continue reading →

Myriad Genetics, Inc. ( MYGN ) reported encouraging results from a pivotal clinical utility study of its myPath Melanoma test at the 2014 College of American Pathologists (CAP) annual meeting in Chicago. myPath Melanoma is a clinically validated gene expression molecular test that has been designed to differentiate malignant melanoma from benign skin lesions, with more than 90% accuracy. This study evaluated 687 pigmented skin lesions submitted by 42 dermatopathologists who were then asked to document their diagnosis, level of confidence, further testing and treatment recommendations, both pre- and post-receipt of the myPath test results. The results showed that 35% of these dermatologists revised their treatment recommendation after receiving the myPath Melanoma test score. Moreover, the test score led to a 76% reduction in "indeterminate" diagnoses. According to Myriad, these data support the integration of myPath Melanoma into clinical practice for improvement of the diagnosis of melanoma, thereby enhancing the scope of patient care. With certain melanomas imitating benign skin lesions, it becomes quite difficult for clinicians to diagnose the former in patients accurately. In such situations, Myriad myPath Melanoma comes of help as it has the ability to discriminate malignant melanoma from benign skin lesions. Management at Myriad strongly … Continue reading →